Status:

UNKNOWN

CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Lead Sponsor:

Hebei Senlang Biotechnology Inc., Ltd.

Collaborating Sponsors:

Hebei Yanda Ludaopei Hospital

Beijing Lu Daopei Hospital

Conditions:

Leukemia

Lymphoma

Eligibility:

All Genders

1-70 years

Phase:

PHASE1

PHASE2

Brief Summary

This is an open, single-arm, phase I/phase II clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of hematopoietic and lymphoid ma...

Detailed Description

Chimeric antigen receptor (CAR)-modified T cells targeted against CD19 have demonstrated unprecedented successes in treating patients with hematopoietic and lymphoid malignancies. Besides CD19, many o...

Eligibility Criteria

Inclusion

  • Be diagnosed a kind of Relapsed or Refractory Haematopoietic and Lymphoid Malignancies:
  • ECOG score≤2;
  • To be aged 1 to 70 years;
  • More than a month lifetime from the consent signing date.

Exclusion

  • Serious cardiac insufficiency, left ventricular ejection fraction\<50%;
  • Has a history of severe pulmonary function damaging;
  • Merging other progressing malignant tumor;
  • Merging uncontrolled infection;
  • Merging the metabolic diseases (except diabetes);
  • Merging severe autoimmune diseases or immunodeficiency disease;
  • Patients with active hepatitis B or hepatitis C;
  • Patients with HIV infection;
  • Has a history of serious allergies on Biological products (including antibiotics);
  • Has acute GvHD on allogeneic hematopoietic stem cell transplantation patients after stopping immunosuppressants a month;
  • Pregnancy or lactation women;
  • Any situation that would increase dangerousness of subjects or disturb the outcome of the clinical study according to the researcher's evaluation.

Key Trial Info

Start Date :

August 29 2017

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 29 2023

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT03312205

Start Date

August 29 2017

End Date

August 29 2023

Last Update

January 9 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hebei Yanda Ludaopei Hospital

Langfang, Hebei, China, 065000